<DOC>
	<DOCNO>NCT02417324</DOCNO>
	<brief_summary>The I-HIT-MED registry register clinical child adult medulloblastoma , ependymoma , pineoblastoma , CNS-primitive neuroectodermal tumour ( CNS-PNET ) Germany country fulfil national ethic requirement participation registry . These tumour rare disease , many patient treat outside clinical trial . The I-HIT-MED registry allow collection data und biological material patient , provide basis standard treatment recommendation counsel . It aim improve international cooperation medical knowledge rare disease . Within I-HIT-MED registry , goal maintain improve network quality assurance national group already establish , support implementation national group , quality assurance network yet .</brief_summary>
	<brief_title>International HIT-MED Registry ( I-HIT-MED )</brief_title>
	<detailed_description>The following patient include registry : Children adult - Medulloblastoma ( MB ) - Ependymoma - CNS-primitive neuroectodermal tumour ( CNS-PNET ) include CNS neuroblastoma , CNS ganglioneuroblastoma , Medulloepithelioma , Ependymoblastoma , CNS-PNET otherwise specify ( NOS ) - Pineoblastoma - Pineal parenchymal tumour intermediate differentiation - Papillary tumour pineal region Who include prospective clinical trial condition The objective registry - To evaluate clinical data epidemiology mention CNS-neoplasms , use outcome different treatment regimen , patient include prospective trial . - To provide guideline establish , maintain improve system quality assurance diagnostic assessment treatment brain tumour . To collect biological specimen ( tumour , cerebrospinal fluid ( CSF ) , peripheral blood ) perform comprehensive biological study aim improve understanding disease aetiology , improve therapy stratification improve develop new treatment option . - To collect clinical data cooperative scientific project ( e.g . new follow-up study , study quality survival , neuropsychology etc . )</detailed_description>
	<mesh_term>Medulloblastoma</mesh_term>
	<criteria>patient mention diagnosis age ( except ependymoma WHO IÂ° , pineal parenchymal tumour intermediate differentiation papillary tumour pineal region , register primary diagnosis 18th birthday ) localisation primary tumour clinical stage First diagnosis 01.01.2012 No inclusion prospective clinical trial diagnosis , due noneligibility , national lack trial approval , individual refusal participation . Written informed consent data transfer tumour sample submission accord law participate country necessary . National and/ local ethical committee approval accord law participate country necessary . Registration another clinical trial diagnosis ( relapse define second diagnosis ) . Lack valid ethical committee approval .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>medulloblastoma</keyword>
	<keyword>ependymoma</keyword>
	<keyword>pineoblastoma</keyword>
	<keyword>CNS-PNET</keyword>
</DOC>